Invesco Ltd. Sells 184,105 Shares of Harrow, Inc. (NASDAQ:HROW)

Invesco Ltd. cut its holdings in Harrow, Inc. (NASDAQ:HROW - Free Report) by 92.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 14,919 shares of the company's stock after selling 184,105 shares during the period. Invesco Ltd.'s holdings in Harrow were worth $501,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of HROW. AlphaQuest LLC lifted its stake in shares of Harrow by 452.8% during the 4th quarter. AlphaQuest LLC now owns 3,527 shares of the company's stock valued at $118,000 after buying an additional 2,889 shares in the last quarter. Federated Hermes Inc. purchased a new position in shares of Harrow in the fourth quarter valued at about $214,000. Maridea Wealth Management LLC purchased a new stake in shares of Harrow during the fourth quarter worth about $222,000. KLP Kapitalforvaltning AS bought a new stake in Harrow during the 4th quarter valued at approximately $235,000. Finally, China Universal Asset Management Co. Ltd. lifted its holdings in Harrow by 10.7% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 7,552 shares of the company's stock worth $253,000 after purchasing an additional 727 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company's stock.

Harrow Price Performance

Harrow stock traded up $0.47 during midday trading on Wednesday, reaching $24.59. 317,845 shares of the stock traded hands, compared to its average volume of 504,302. The stock has a market cap of $902.08 million, a P/E ratio of -26.16 and a beta of 0.41. The stock's fifty day moving average is $24.94 and its 200-day moving average is $33.33. The company has a quick ratio of 1.44, a current ratio of 1.55 and a debt-to-equity ratio of 3.23. Harrow, Inc. has a 12 month low of $10.08 and a 12 month high of $59.23.

Harrow (NASDAQ:HROW - Get Free Report) last posted its earnings results on Thursday, March 27th. The company reported $0.25 EPS for the quarter, beating analysts' consensus estimates of $0.11 by $0.14. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. The firm had revenue of $66.83 million during the quarter, compared to the consensus estimate of $66.01 million. As a group, equities research analysts anticipate that Harrow, Inc. will post -0.53 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on HROW shares. B. Riley cut their price objective on shares of Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. HC Wainwright reaffirmed a "buy" rating and set a $57.00 target price on shares of Harrow in a research note on Monday, March 31st.

About Harrow

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.